Literature DB >> 14738931

Determination of celecoxib in human plasma using solid-phase extraction and high-performance liquid chromatography.

H-H Sherry Chow1, Nathan Anavy, Dawn Salazar, Denise H Frank, David S Alberts.   

Abstract

A simple reversed phase high-performance liquid chromatography (HPLC) method was developed for determination of celecoxib levels in human plasma. The procedure involves solid-phase extraction of celecoxib and the internal standard (SC-236) from plasma using C(18) extraction cartridges. The chromatographic separation of celecoxib and SC-236 was achieved with a Nova Pak C(8) column (3.8 mm x 150 mm) eluted with a mobile phase consisting of acetonitrile-tetrahydrofuran-sodium acetate buffer (pH 5.0) in the ratio of 30:8:62. An ultraviolet light detector with the wavelength set at 215 nm was employed for detection. Celecoxib was well resolved from the plasma constituents and the internal standard. The extraction recovery of celecoxib and SC-236 from human plasma was greater than 88%. Linear calibration curves were established over a concentration range of 40-4000 ng/ml when 0.25 ml aliquots of plasma were used. The inter- and intra-day R.S.D. for the assay was less than 12 and 5%, respectively. This assay has been applied to the analysis of celecoxib levels in plasma samples collected from healthy participants entered into a Phase II clinical study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14738931     DOI: 10.1016/j.japna.2003.08.018

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Determination of epinephrine in pharmaceutical formulation by an optimized novel luminescence method using CdS quantum dots as sensitizer.

Authors:  Seyed Naser Azizi; Mohammad Javad Chaichi; Parmis Shakeri; Ahmadreza Bekhradnia
Journal:  J Fluoresc       Date:  2012-10-11       Impact factor: 2.217

2.  Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.

Authors:  Patricia A Thompson; Erin L Ashbeck; Denise J Roe; Liane Fales; Julie Buckmeier; Fang Wang; Achyut Bhattacharyya; Chiu-Hsieh Hsu; Sherry H H Chow; Dennis J Ahnen; C Richard Boland; Russell I Heigh; David E Fay; Stanley R Hamilton; Elizabeth T Jacobs; Elena Maria Martinez; David S Alberts; Peter Lance
Journal:  J Natl Cancer Inst       Date:  2016-08-16       Impact factor: 13.506

3.  Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo.

Authors:  Parisa Abedinpour; Véronique T Baron; John Welsh; Per Borgström
Journal:  Prostate       Date:  2010-11-04       Impact factor: 4.104

4.  Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.

Authors:  Patricia Thompson; Denise J Roe; Liane Fales; Julie Buckmeier; Fang Wang; Stanley R Hamilton; Achyut Bhattacharyya; Sylvan Green; Chiu-Hsieh Hsu; H-H Sherry Chow; Dennis J Ahnen; C Richard Boland; Russell I Heigh; David E Fay; Maria Elena Martinez; Elizabeth Jacobs; Erin L Ashbeck; David S Alberts; Peter Lance
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-11

5.  Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women.

Authors:  Edward R Sauter; Wenyi Qin; John E Hewett; Rachel L Ruhlen; John T Flynn; George Rottinghaus; Yin-Chieh Chen
Journal:  BMC Cancer       Date:  2008-02-11       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.